GridAI Technologies (GRDX) Income from Continuing Operations (2015 - 2025)
GridAI Technologies' (GRDX) quarterly Income from Continuing Operations came in at 4046124.0 in Q4 2025, down 238.85% YoY from 2914017.74 in Q4 2024, and down 316.76% on a QoQ basis from 970856.0 in Q3 2025.
GridAI Technologies (GRDX) Income from Continuing Operations (2015 - 2025) Analysis & Trends
GridAI Technologies (GRDX) has 11 years of Income from Continuing Operations data on file, last reported at 4046124.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 238.85% year-over-year to 4046124.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 6640016.0 (down 32.42% YoY) and the FY2025 annual result came in at 6241280.0, up 60.04% from the prior year.
- Income from Continuing Operations retreated to 4046124.0 in Q4 2025, from 970856.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5760414.0 in Q1 2024 to a low of 30927026.0 in Q3 2021.
- A 5-year average of 5022953.0 and a median of 4058388.5 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations sank 482.0% — and 2024, when it soared 241.51%.
- Tracing GRDX's Income from Continuing Operations over 5 years: stood at 11169376.0 in 2021, then soared by 79.58% to 2281178.0 in 2022, then sank by 79.85% to 4102752.0 in 2023, then surged by 70.9% to 1194074.0 in 2024, then plunged by 238.85% to 4046124.0 in 2025.
- The last three Income from Continuing Operations figures came in at 4046124.0 (Q4 2025), 970856.0 (Q3 2025), and 674931.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | GridAI Technologies | 5.82 Mn | 5.82 Mn | - | -4.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.05 Mn |
| Sep 30, 2025 | -970,856.00 |
| Jun 30, 2025 | -674,931.00 |
| Mar 31, 2025 | -948,105.00 |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -1.90 Mn |
| Jun 30, 2024 | -7.69 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Dec 31, 2023 | -4.10 Mn |
| Sep 30, 2023 | -3.43 Mn |
| Jun 30, 2023 | -4.19 Mn |
| Mar 31, 2023 | -4.07 Mn |
| Dec 31, 2022 | -2.28 Mn |
| Sep 30, 2022 | 4.05 Mn |
| Jun 30, 2022 | -5.77 Mn |
| Mar 31, 2022 | -9.43 Mn |
| Dec 31, 2021 | -11.17 Mn |
| Sep 30, 2021 | -30.93 Mn |
| Jun 30, 2021 | -9.80 Mn |
| Mar 31, 2021 | -7.69 Mn |